Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | Cancer Communications |
| Online Access: | https://doi.org/10.1002/cac2.12474 |
| _version_ | 1797662035643727872 |
|---|---|
| author | Zhenzhen Wang Yang Lu Yu Liu Junli Mou Xiaoyu Liu Manling Chen Ying Wang Yingxi Xu Qing Rao Haiyan Xing Kejing Tang Zheng Tian Bing Wang Wei Qi Min Wang Shaowei Qiu Dongsheng Xiong Jianxiang Wang |
| author_facet | Zhenzhen Wang Yang Lu Yu Liu Junli Mou Xiaoyu Liu Manling Chen Ying Wang Yingxi Xu Qing Rao Haiyan Xing Kejing Tang Zheng Tian Bing Wang Wei Qi Min Wang Shaowei Qiu Dongsheng Xiong Jianxiang Wang |
| author_sort | Zhenzhen Wang |
| collection | DOAJ |
| first_indexed | 2024-03-11T18:54:15Z |
| format | Article |
| id | doaj.art-0e847548875a41cabe1da6794ef1c6ff |
| institution | Directory Open Access Journal |
| issn | 2523-3548 |
| language | English |
| last_indexed | 2024-03-11T18:54:15Z |
| publishDate | 2023-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Communications |
| spelling | doaj.art-0e847548875a41cabe1da6794ef1c6ff2023-10-11T06:53:59ZengWileyCancer Communications2523-35482023-10-0143101178118210.1002/cac2.12474Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicityZhenzhen Wang0Yang Lu1Yu Liu2Junli Mou3Xiaoyu Liu4Manling Chen5Ying Wang6Yingxi Xu7Qing Rao8Haiyan Xing9Kejing Tang10Zheng Tian11Bing Wang12Wei Qi13Min Wang14Shaowei Qiu15Dongsheng Xiong16Jianxiang Wang17State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaNovogene Co, Ltd BeijingP. R. ChinaNovogene Co, Ltd BeijingP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. ChinaState Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Tianjin Key Laboratory of Cell Therapy for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College TianjinP. R. Chinahttps://doi.org/10.1002/cac2.12474 |
| spellingShingle | Zhenzhen Wang Yang Lu Yu Liu Junli Mou Xiaoyu Liu Manling Chen Ying Wang Yingxi Xu Qing Rao Haiyan Xing Kejing Tang Zheng Tian Bing Wang Wei Qi Min Wang Shaowei Qiu Dongsheng Xiong Jianxiang Wang Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity Cancer Communications |
| title | Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity |
| title_full | Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity |
| title_fullStr | Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity |
| title_full_unstemmed | Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity |
| title_short | Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity |
| title_sort | novel cd123 cd33 bicistronic chimeric antigen receptor car t therapy has potential to reduce escape from single target car t with no more hematotoxicity |
| url | https://doi.org/10.1002/cac2.12474 |
| work_keys_str_mv | AT zhenzhenwang novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT yanglu novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT yuliu novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT junlimou novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT xiaoyuliu novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT manlingchen novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT yingwang novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT yingxixu novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT qingrao novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT haiyanxing novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT kejingtang novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT zhengtian novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT bingwang novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT weiqi novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT minwang novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT shaoweiqiu novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT dongshengxiong novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity AT jianxiangwang novelcd123cd33bicistronicchimericantigenreceptorcarttherapyhaspotentialtoreduceescapefromsingletargetcartwithnomorehematotoxicity |